Recently added

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

Nag, Shona; ray coquard, isabelle; Gupta, Sudeep; Pathak, Anand; Lopez, Jose Rafael; Mulya Sari, Resti; OAKNIN, ANA (Elsevier, 2025-06)

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Lundberg, Ante S.; Geuijen, Cecile A. W.; Hill, Sally; Lammerts van Bueren, Jeroen J.; Fumagalli, Arianna; de Kruif, John; Tabernero, Josep (MDPI, 2025-05)

Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort

Osterlund, Emerik; Sjöblom, Tobias; Hammarström, Klara; Nunes, Luis; Mathot, Lucy; Mezheyeuski, Artur (Springer Nature, 2025-05-28)

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab

Elez, Elena; Calleja, Elizabeth; Caussé-Amellal, Nadia; Fakih, Marwan; Ciardiello, Fortunato; Prager, Gerhard (Elsevier, 2025-09)

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Babiker, Hani M.; Picozzi, Vincent J.; Chandana, Sreenivasa R; Melichar, Bohuslav; Kasi, Anup; Gang, Jin; Macarulla, Teresa (American Society of Clinical Oncology, 2025-07-20)

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Scientia. Department of Health Digital Information Depot

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer ﻿

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications ﻿

Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort ﻿

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab ﻿

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study ﻿

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort

Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study